Prior to joining CIC Anne was a Partner at Advent France Biotechnology (now AdBio Partners), a Paris-based venture capital firm specialising in seed investments and company creation, and Senior Associate at Sofinnova Partners.
Anne started her career as a Senior Medicinal Chemist at Cambridge Biotechnology Ltd (now part of Benevolent AI) before joining Cancer Research Technology (now Cancer Research Horizons) as Business Development Executive.
Anne brings over 20 years’ experience, spanning across all aspects of Life Sciences innovation from drug discovery, technology transfer and business development to equity financing.
Anne carried out postdoctoral research at Yale University after her PhD in synthetic organic chemistry from the University of Bristol. She holds a diplôme d’ingénieur (Chemistry) from the Institut National des Sciences Appliquées de Rouen, authored several peer-reviewed papers and is an inventor on eight patent families. She was recently elected to the board of the BioIndustry Association and as an Industry and Enterprise Fellow at Clare Hall, University of Cambridge.
Anne manages CIC's investment in Complement Therapeutics, Microbiotica and T-Therapeutics as well as the Start Codon portfolio companies.